CMMB News and Press, Chemomab Therapeutics Ltd. From 12/21/22

Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis PR Newswire —Clean Safety Review Supports Addition of Higher Dose Cohort into the Trial — TEL AVIV, Israel , Dec. ...

Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy PR Newswire TEL AVIV, Israel ...

Chemomab Therapeutics ( NASDAQ: CMMB ) announced Monday the appointment of Matthew Frankel, MD, MBA as its new chief medical officer and vice president of drug development. Frankel most recently served as VP, Clinical Development and Medical Affairs, Special...

Chemomab Therapeutics Ltd. (CMMB) Q3 2022 Earnings Conference Call November 11, 2022, 08:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Don Marvin - Ch...

Chemomab Therapeutics - ADR press release ( NASDAQ: CMMB ): Q3 GAAP EPS of -$0.04 beats by $0.19 . Cash and cash equivalents were $46.5M as of September 30, 2022, compared to $51.8M as of June 30, 2022. The company currently expects its runway to last through year-...

Chemomab Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update PR Newswire ─ Chemomab to Host Conference Call for Investors Today, November 11 at 8:00 am ET ─ TEL AVIV, Israel , Nov. 11...

Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19 PR Newswire ─New Findings Demonstrate CM-101's Anti-Inflammatory a...

Chemomab Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Business Update PR Newswire TEL AVIV, Israel , Nov. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology compa...

Chemomab Therapeutics to Present at Upcoming Scientific Conferences PR Newswire TEL AVIV, Israel , Oct. 28, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery an...

Chemomab Therapeutics Ltd. (CMMB) Q2 2022 Earnings Conference Call August 12, 2022 08:00 ET CompanyParticipants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer David Weiner - Interim...